CTD 12.5 mg Ipca Laboratories Ltd
| Features | |
| Active substance | Chlorthalidone |
| Also known as | Chlortalidone |
| Blood pressure | Lowers blood pressure |
| Chemical name | 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide |
| Dosage (medical) | Commonly 12.5 mg to 25 mg daily for hypertension |
| Dosage (sports) | Not applicable for sports enhancement |
| Effects | Reduces blood pressure, decreases fluid retention |
| Formula | C14H11ClN2O4S |
| Half-life | Approximately 40 to 60 hours |
| Hepatotoxicity | Minimal risk |
| Lab Test | Can affect electrolyte and glucose levels |
| Main action | Diuresis and antihypertensive |
| Side effects | Dizziness, dehydration, hypokalemia, hyperglycemia, increased uric acid |
| Storage conditions | Store at room temperature away from moisture and heat |
| Strength | 12.5mg |
| Substance class | Thiazide-like diuretic |
| Trade name | Hygroton, Thalitone |
| Use in sports | Not typically used in sports, potential for misuse in weight class sports for rapid weight loss |
| Water Retention | Reduces water retention |
| Manufacturer | Ipca Laboratories Ltd |
| Packing | 15 tabs/blister |